Diffuse Large B-Cell Lymphoma: Sequencing Therapy for Relapsed/Refractory Disease
The advent of novel targeted therapies represents a major paradigm shift for management of relapsed or refractory diffuse large B-cell lymphomas (DLBCL).
Category
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Cost $0.00
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updates in Prognosis and Treatment
The prognostic significance of molecular and cytogenetic variables vary depending on the treatment regimens and clinical outcomes being evaluated.
Category
- Chronic Lymphocytic Leukemia
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Cost $0.00
What is Optimal First-Line Management of Advanced Classic Hodgkin Lymphoma?
Given the high cure rate of classic Hodgkin lymphoma, clinical trials strive to reduce potential long-term toxicities of treatment.
Category
- Hodgkin Lymphoma
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Cost $0.00